Atea Pharmaceuticals Inc (AVIR) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Atea Pharmaceuticals Inc stock (AVIR) is currently trading at $5.33. Atea Pharmaceuticals Inc PS ratio (Price-to-Sales) is 1.90. Analyst consensus price target for AVIR is $8.83. WallStSmart rates AVIR as Underperform.
- AVIR PE ratio analysis and historical PE chart
- AVIR PS ratio (Price-to-Sales) history and trend
- AVIR intrinsic value — DCF, Graham Number, EPV models
- AVIR stock price prediction 2025 2026 2027 2028 2029 2030
- AVIR fair value vs current price
- AVIR insider transactions and insider buying
- Is AVIR undervalued or overvalued?
- Atea Pharmaceuticals Inc financial analysis — revenue, earnings, cash flow
- AVIR Piotroski F-Score and Altman Z-Score
- AVIR analyst price target and Smart Rating
Atea Pharmaceuticals Inc
📊 No data available
Try selecting a different time range
Smart Analysis
Atea Pharmaceuticals Inc (AVIR) · 7 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in price/sales, price/book, revenue growth. Concerns around return on equity. Fundamentals are solid but monitor weak areas for improvement.
Atea Pharmaceuticals Inc (AVIR) Key Strengths (5)
Revenue surging 295.20% year-over-year
Earnings per share surging 264.10% year-over-year
76.82% of shares held by major funds and institutions
Paying $1.90 for every $1 of annual revenue
Trading at 1.64x book value, attractively priced
Supporting Valuation Data
Atea Pharmaceuticals Inc (AVIR) Areas to Watch (2)
Company is destroying shareholder value
Small-cap company with higher risk but more growth potential
Supporting Valuation Data
Atea Pharmaceuticals Inc (AVIR) Detailed Analysis Report
Overall Assessment
This company scores 51/100 in our Smart Analysis, earning a C- grade. Out of 7 metrics analyzed, 5 register as strengths (avg 9.2/10) while 2 fall into concern territory (avg 2.5/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Revenue Growth, EPS Growth, Institutional Own.. Valuation metrics including Price/Sales (1.90), Price/Book (1.64) suggest the stock is attractively priced. Growth metrics are encouraging with Revenue Growth at 295.20%, EPS Growth at 264.10%.
The Bear Case
The primary concerns are Return on Equity, Market Cap. Profitability pressure is visible in Return on Equity at -44.30%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -44.30% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 295.20% strong but requiring continuation.
Risk Considerations
Based on the metric profile, this is a moderate-to-high risk investment. The weight of evidence leans positive, with more strengths than concerns. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Mixed fundamentals with both positives (Revenue Growth, EPS Growth) and negatives (Return on Equity, Market Cap). A cautious approach is warranted. Monitor for improvement in weak areas before increasing conviction.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
AVIR Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
AVIR's Price-to-Sales ratio of 1.90x sits near its historical average of 1.9x (0th percentile), suggesting the market is pricing in steady-state growth. The current valuation is 0% below its historical high of 1.9x set in Feb 2026, and 0% above its historical low of 1.9x in Feb 2026.
WallStSmart Analysis Synopsis
Data-driven financial summary for Atea Pharmaceuticals Inc (AVIR) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Atea Pharmaceuticals Inc is in a high-growth phase, prioritizing rapid expansion over margins. Revenue reached 192M with 295% growth year-over-year.
Key Findings
Revenue growing at 295% YoY, reaching 192M. This pace significantly outperforms most BIOTECHNOLOGY peers.
Debt-to-equity ratio of 0.00 indicates a conservative balance sheet with 77M in cash.
Free cash flow is -28M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Growth sustainability: can Atea Pharmaceuticals Inc maintain 295%+ revenue growth, or will competition slow it down?
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Atea Pharmaceuticals Inc.
Bottom Line
Atea Pharmaceuticals Inc is a high-conviction growth story with revenue accelerating at 295% while profitability is still developing. For growth-oriented investors, the trajectory is compelling. For value investors, the thin 0.0% margins and premium valuation suggest patience until the unit economics mature further.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Atea Pharmaceuticals Inc(AVIR)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing antiviral therapies for patients suffering from viral infections. The company is headquartered in Boston, Massachusetts.